Turkish Journal of
GERIATRICS

¹Clinic Kadın SaÄŸlığı Ä°nfertilite ve Tüp Bebek Merkezi, ANKARA
²Kadın Hastalıkları ve DoÄŸum Uzmanı Serbest Hekim, ANKARA
³Hacettepe Ãœniversitesi Tıp Fakültesi Kadın Hastalıkları ve DoÄŸum Anabilim Dalı, ANKARA Osteoporosis is a common condition in postmenopausal women and is associated with morbidity and mortality. It is clear that long-term hormone therapy (HT) has a role to play in preventing osteoporosis by increasing bone mineral density and reducing fracture rate. Although hormone therapy has demonstrated clinical fracture risk reduction; safety outcomes from the Women's Health Initiative (WHI) study have raised concerns regarding long-term use of HT. However WHI suggesting that the incidence of breast cancer, coronary heart disease, stroke, and venous thromboembolism increases following long-term use of HT. In conlusion, estrogen is an option for the prevention of osteoporosis in perimenopausal women, but we no longer consider it a first-line therapy. Keywords : Postmenopausal osteoporosis, Management, Hormon therapy, Estrogen